2021.Apr.10
Vaccine
What We Do
學術發表
2021.Apr.10
Prodrug
Selective and Broad Anti-tumor Activity of AKR1C3-activated Prodrug AST-3424/OBI-3424
2021.Apr.10
ADC
Preclinical characterization of a novel SSEA4-targeting antibody drug conjugate, OBI-998
2020.Nov.19
Vaccine
A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients
2020.Nov.19
Vaccine
OBI-833 was safe and immunogenic, without treatment-related SAEs, in a phase I dose-escalation trial
2020.May.29
Prodrug
A First-In-Man Phase 1/2 Study of OBI-3424, an AKR1C3-Selective Bis-Alkylating Agent Prodrug, in Subjects With Advanced Cancer, Including Hepatocellular Carcinoma (HCC) and Castrate-Resistant Prostate Cancer (CRPC)
2020.May.29
Vaccine
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High Risk, Early-Stage, Globo H-Positive, Triple Negative Breast Cancer
2020.May.29
ADC
A Phase 1/2, Open‑Label, Dose-Escalation, and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI‑999 in Patients with Advanced Solid Tumors.
2019.Jul.21
ADC